NIVELLES, Belgium — Univercells Technologies, a Donaldson Life Sciences company, has introduced the scale-X™ nitro controller, a new addition to its scale-X bioreactor platform aimed at simplifying and accelerating the path from research to commercial-scale viral and advanced therapy manufacturing.
Designed to operate both 200 m² and 600 m² fixed-bed bioreactors, the nitro controller offers high productivity in a compact, user-friendly format. With a footprint of just 1.6 m² and a height under 2 meters, the system is delivered as a single, wheeled unit that can be rolled directly into cleanrooms and production suites—dramatically reducing setup time and infrastructure demands.
According to Univercells, the scale-X nitro controller enables rapid scalability from lab-scale research to full commercial production in as little as eight months. It supports both adherent and suspension cell cultures, making it suitable for a range of applications, including viral vaccines, exosomes, lentiviral and AAV vectors, oncolytic viruses, and recombinant proteins.
“This launch completes our vision of a fully scalable, high-performance solution for viral vector and vaccine manufacturing,” said Marie Jourdan, Director of the Bioprocessing Product Portfolio at Univercells Technologies. “The nitro controller makes large-scale production accessible to biotech firms, CDMOs, and academic labs without the complexity or costs typically involved.”
The system integrates with the company’s existing NevoLine™ platform and offers simplified operations through an intuitive interface and easy-to-install flow paths. Univercells reports that the nitro controller can help reduce production costs by 36% to 82% compared to other adherent cell culture methods.
The launch marks a significant step in Univercells’ efforts to democratize access to advanced therapy manufacturing technology, enabling more efficient production while lowering economic and infrastructure barriers for industry and research institutions worldwide.
